We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session

Sunday
May 14
10:30 - 11:30
Stolz 1
Lung
Corinne Faivre-Finn, United Kingdom;
Daniel Zips, Germany
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will not be recorded.
2280
Mini-Oral
Clinical
Impact of the COVID-19 pandemic on patient outcomes after curative-intent radiotherapy in the UK
Isabella Fornacon-Wood, United Kingdom
MO-0467
Impact of gross vascular invasion on NSCLC outcomes: propensity matched cohort analysis
Atazhan Ushkempirov, Kazakhstan
MO-0468
The addition of immunotherapy to lung cancer chemoradiotherapy: Factors associated with survival
Huei-Tyng Huang, United Kingdom
MO-0469
IMPT reduces esophageal and pulmonary toxicity compared to VMAT in stage II-IV NSCLC patients
Arno Hessels, The Netherlands
MO-0470
Post-radiotherapy G3+ esophageal toxicity predictors: Pooled data from 2,131 lung cancer patients
Azadeh Abravan, United Kingdom
MO-0471
Prospective trial of functional lung avoidance radiation for lung cancer: quality of life report
Brian Kavanagh, USA
MO-0472
Lymphopenia during NSCLC ChemoRT is proportional to FLT-detected suppression of irradiated marrow
Michael MacManus, Australia
MO-0473
Is comorbidity associated with interruption of RT treatment in patients with lung cancer?
Golnoosh Motamedi-Ghahfarokhi, United Kingdom
MO-0474